-
Okadaic acid: PP1/PP2A Workflow Guide
2026-08-28
Okadaic acid (A4540) provides a controlled way to inhibit serine/threonine phosphatases PP2A and PP1 when phosphorylation-dependent signaling or apoptosis-related endpoints must be interrogated. It is suitable for biochemical and cell-based studies with matched vehicle controls, but it should not be treated as a broad phosphatase inhibitor or as evidence that a downstream phenotype is specific to one pathway.
-
Humanized Mice Clarify HD56 Prodrug Pharmacokinetics
2026-08-27
A 2025 Drug Metabolism and Disposition study shows that humanized-liver mice can resolve species-dependent metabolism of the carboxylesterase-activated prodrug HD56 more effectively than conventional preclinical species. Its strong in vivo–in vitro correlation supports humanized models as a practical tool for improving pharmacokinetic prediction during ester-prodrug development.
-
Pentoxifylline and LPS Inflammation in Preterm Monocytes
2026-08-27
Schüller and colleagues examined how pentoxifylline reshapes LPS-triggered monocyte responses across preterm infants, term infants, and adults. The study links reduced inflammatory cytokines and surface activation markers to suppression of TLR4 expression and signaling, while also identifying age-dependent effects that are important for neonatal sepsis research.
-
HyperFusion high-fidelity DNA polymerase Workflow
2026-08-26
Build more reliable C. elegans neurodegeneration assays with a proofreading DNA polymerase designed for accurate, rapid amplification of long, GC-rich, or inhibitor-laden templates. HyperFusion™ combines high fidelity, blunt-end products, and a streamlined reaction format for cloning, genotyping, and sequencing-oriented workflows.
-
HyperFusion™ high-fidelity DNA polymerase Guide
2026-08-26
A scenario-driven guide to using HyperFusion™ high-fidelity DNA polymerase (SKU K1032) for molecular validation in cell viability, proliferation, and cytotoxicity workflows. It explains how proofreading fidelity, inhibitor tolerance, and simple reaction setup can support more dependable PCR-based genotyping, cloning, and sequencing decisions.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-08-25
MDL 28170 combines nanomolar calpain inhibition with cell permeability and brain exposure, making it useful for mechanistic neuroprotection research as well as selected cardiac and infectious-disease models. This guide translates the compound’s properties and recent BDNF/TrkB findings into practical workflows, controls, and troubleshooting decisions.
-
Crystal Violet in C. auris Translational Research
2026-08-25
A translational framework for using Crystal Violet Staining Solution as a rigorous imaging endpoint while interpreting Candidozyma auris phenotypes alongside genomic, antifungal susceptibility, virulence, and biofilm data.
-
Wortmannin Reveals Clathrin-Mediated GCRV Entry
2026-08-24
Wang et al. used pharmacological inhibition, transmission electron microscopy, and real-time quantitative PCR to show that genotype III grass carp reovirus enters grass carp kidney cells through a clathrin-mediated, dynamin-dependent, acidification-sensitive pathway. The study also identifies Wortmannin and rottlerin as inhibitors of GCRV104 entry and replication, providing a useful mechanistic framework for antiviral and host-pathway research.
-
Antipyrine: BBB and Pharmacokinetic Research
2026-08-24
Antipyrine, also known as 1,5-dimethyl-2-phenylpyrazol-3-one, is a high-purity analgesic and antipyretic research compound with reported water solubility of at least 66.3 mg/mL under unspecified assay conditions. Its defined physicochemical profile makes it useful for pharmacokinetic studies, but the cited LLC-PK1-MDR1 study does not establish Antipyrine-specific blood-brain barrier performance.
-
β-Pseudouridine B8649 for Reliable RNA Assays
2026-08-23
Learn how β-Pseudouridine (SKU B8649) can support controlled RNA-modification experiments while reducing interpretation errors in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers experimental controls, preparation, assay compatibility, data analysis, and practical reagent selection.
-
Toremifene Citrate: Evidence from Fareston®
2026-08-22
The reference article presents toremifene citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator for postmenopausal women with locally advanced or metastatic, hormone receptor-positive or unknown-status breast cancer. Its practical contribution is to connect estrogen receptor pharmacology, comparative efficacy with tamoxifen, pharmacokinetics, safety monitoring, and treatment sequencing in a clinically usable framework.
-
From AI Signatures to qPCR-Ready HCC Validation
2026-08-21
A translational framework for converting an artificial intelligence-derived hepatocellular carcinoma prognostic signature into a reproducible gene expression assay, with mechanistic context, validation checkpoints, and strategic guidance for dye-based qPCR workflows.
-
Lipid Peroxidation (MDA) Assay Kit K2167
2026-08-20
The Lipid Peroxidation (MDA) Assay Kit K2167 quantifies malondialdehyde in biological samples through TBA-based colorimetric or fluorescence detection. Its reported 1–200 μM linear range supports oxidative stress biomarker assay workflows, while orthogonal ferroptosis measurements remain necessary for pathway attribution.
-
Machine-Learning Discovery of New Senolytics
2026-08-20
The reference study shows that cost-effective machine-learning models trained on published screening data can identify senolytic candidates despite limited and heterogeneous datasets. Computational prioritization followed by cell-based validation revealed ginkgetin, periplocin, and oleandrin as active senolytics, while demonstrating a substantial reduction in early-stage screening costs.
-
α2-AR Agonism in Osteosarcoma Recurrence
2026-08-19
The reference study evaluates UK14,304 delivered in a thermosensitive PLGA-PEG-PLGA hydrogel as a local strategy for limiting post-surgical osteosarcoma recurrence. Its data indicate that the effect is driven less by direct tumor-cell toxicity than by immune activation involving CD8+ T cells, T-cell receptor signaling, and the regulatory protein ITGAL.